Zyclara (imiquimod) NDC 99207-270

NDC codes

FDA NDC Directory

Product NDC (as listed)99207-270Labeler and product segments. Claims need a package NDC.

Product NDC at billing width99207-0270Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
99207-270-01	99207027001	4 PACKET in 1 CARTON (99207-270-01) / .25 g in 1 PACKETMarketed from Nov 28, 2011

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Zyclara
Generic name (nonproprietary): imiquimod
Active ingredients: Imiquimod — 37.5 mg/g
Dosage form: Cream
Route: Topical
Labeler: Bausch Health US, LLC
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 022483
Marketing start: Nov 28, 2011
Listing expires: Dec 31, 2027
Other FDA classes: Increased Cytokine Activity (Physiologic effect)Increased Cytokine Production (Physiologic effect)Interferon Inducers (Mechanism)
Identifiers: Product ID 99207-270_1216e839-274f-412d-953f-ce56f0cd42a2SPL ID 1216e839-274f-412d-953f-ce56f0cd42a2SPL set ID 28cd9b5b-680b-480f-b33d-9c5b52bbf03dRxCUI 967017, 967021UNII P1QW714R7M

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Topical products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N499207027001 followed by a unit qualifier and the quantity

Package 99207-0270-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 23, 2025.

Indications (excerpt from the label)

• ZYCLARA 2.5% and 3.75% is indicated for the topical treatment of clinically typical, visible, or palpable actinic keratoses (AK) of the face or balding scalp in immunocompetent adults. ( 1.1 ) • ZYCLARA, 3.75% is indicated for the topical treatment of external genital and perianal warts (EGW) in immunocompetent patients 12 years of age or older. ( 1.2 ) 1.1 Actinic Keratosis ZYCLARA, 2.5% and 3.75% are indicated for the topical treatment of clinically typical, visible or palpable actinic keratoses (AK) of the face or balding scalp in immunocompetent adults. 1.2 External Genital Warts ZYCLARA, 3.75% is indicated for the topical treatment of external genital and perianal warts (EGW) in immun…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 022483

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 022483
Product	Strength	Form · route	Labeler	Product NDC
Imiquimod	Imiquimod 37.5 mg/g	CreamTopical	Teva Pharmaceuticals USA, Inc.	0093-3133
Zyclaraimiquimod	Imiquimod 37.5 mg/g	CreamTopical	Bausch Health US, LLC	99207-271
Zyclaraimiquimod	Imiquimod 2.5 mg/g	CreamTopical	Bausch Health US, LLC	99207-276
Imiquimod	Imiquimod 37.5 mg/g	CreamTopical	Oceanside Pharmacueticals	68682-272